Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : Monsanto loses final appeal over French farmer's weedkiller accident

10/21/2020 | 01:11pm EST
FILE PHOTO: French cereal farmer Paul Francois speaks during a news conference before the start of his appeals trial against U.S. Monsanto firm in Lyon

PARIS (Reuters) - Bayer's Monsanto division on Wednesday lost a final appeal in a long-running French legal battle in which the crop chemical maker has been held liable for the accidental inhalation of a weedkiller by a crop farmer.

Monsanto had been trying to overturn a decision by an appeals court in 2019 that had found the company's product safety information to have been inadequate in relation to the accident involving farmer Paul Francois in 2004.

France's highest court rejected Monsanto's latest appeal in a ruling published on Wednesday, opening the way for another court to decide on what damages should be awarded to Francois.

The farmer has argued that the fumes he inhaled from the weedkiller Lasso, a product that was subsequently withdrawn from the French market, caused neurological problems, including memory loss, fainting and headaches.

Bayer said in an emailed statement that it was reviewing the court ruling. Bayer also said in the statement that court-appointed medical experts had found previously that the incident did not cause the illnesses cited by Francois.

Crop protection products "do not present a risk to human health if they are used under the conditions of use defined in the context of their marketing authorisation," Bayer said.

Anti-pesticide group Generations Futures, which has supported Francois in his court case, said it welcomed "this historic decision in which an agro-chemical multinational is at last found liable for the harm caused to this courageous farmer."

Francois has previously sought damages of around 1 million euros ($1.2 million).

Bayer, which acquired Monsanto for $63 billion in 2018, has been facing a wave of litigation in the United States over allegations that Monsanto's glyphosate-based weedkiller Roundup causes cancer.

Bayer, which argues Roundup is safe, is trying to settle the litigation through a proposed $11 billion payment.

(Reporting by Gus Trompiz. Editing by Jane Merriman)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -0.17% 47.745 Delayed Quote.-34.32%
HUMAN HEALTH HOLDINGS LIMITED 5.56% 0.57 End-of-day quote.-52.50%
All news about BAYER AG
12/03BAYER : establishes Cell and Gene Therapy Platform to accelerate pharmaceutical ..
12/02BAYER : Launches Cell and Gene Therapy Platform
12/02BAYER : sets up cell and gene platform to foster purchased biotech firms
12/01GLOBAL MARKETS LIVE: Bank of America, Pfizer, Tesla…
12/01BAYER : Blackford Analysis to Work on Medical-Imaging Platform
12/01BAYER : and Blackford Analysis to Collaborate on Integration of AI Solutions in ..
12/01BAYER CROPSCIENCE : partners with BigHaat for last mile delivery of agri-inputs
12/01BAYER AG : Bernstein reiterates its Buy rating
12/01BAYER : to Raise $1.65 Billion Through Sale of Elanco Shares
12/01BAYER : announces placement of Elanco shares for gross proceeds of 1.6 billion U..
More news
Sales 2020 42 052 M 51 063 M 51 063 M
Net income 2020 -10 614 M -12 889 M -12 889 M
Net Debt 2020 34 614 M 42 032 M 42 032 M
P/E ratio 2020 -4,17x
Yield 2020 4,61%
Capitalization 46 906 M 56 994 M 56 957 M
EV / Sales 2020 1,94x
EV / Sales 2021 1,90x
Nbr of Employees 100 618
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 61,32 €
Last Close Price 47,75 €
Spread / Highest target 78,0%
Spread / Average Target 28,4%
Spread / Lowest Target -3,65%
EPS Revisions
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-34.32%56 765
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033